50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
S&P 500   3,690.39 (+0.97%)
DOW   29,488.34 (+0.78%)
QQQ   278.11 (+1.36%)
AAPL   153.34 (+1.70%)
MSFT   239.63 (+0.92%)
META   138.37 (+1.47%)
GOOGL   99.06 (+0.91%)
AMZN   115.98 (+0.72%)
TSLA   288.07 (+4.37%)
NVDA   126.59 (+3.52%)
NIO   17.67 (+0.28%)
BABA   79.62 (+0.90%)
AMD   68.20 (+2.87%)
T   16.01 (+2.17%)
MU   50.17 (+2.64%)
CGC   2.91 (+6.20%)
F   12.12 (+1.08%)
GE   65.23 (+1.37%)
DIS   98.96 (+0.86%)
AMC   7.39 (+8.20%)
PYPL   87.24 (+3.54%)
PFE   44.38 (+1.25%)
NFLX   227.91 (+1.71%)
NASDAQ:PRCT

PROCEPT BioRobotics - PRCT Stock Forecast, Price & News

$39.54
+1.47 (+3.86%)
(As of 09/27/2022 10:54 AM ET)
Add
Compare
Today's Range
$38.24
$39.91
50-Day Range
$34.17
$50.65
52-Week Range
$15.38
$52.40
Volume
1,622 shs
Average Volume
450,634 shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.50

PROCEPT BioRobotics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
10.0% Upside
$43.50 Price Target
Short Interest
Healthy
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.83) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

648th out of 1,071 stocks

Surgical & Medical Instruments Industry

70th out of 106 stocks

PRCT stock logo

About PROCEPT BioRobotics (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

PRCT Stock News Headlines

See More Headlines
Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

PRCT Company Calendar

Last Earnings
8/04/2022
Today
9/27/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRCT
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.50
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+10.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-59,850,000.00
Net Margins
-138.49%
Pretax Margin
-138.49%

Debt

Sales & Book Value

Annual Sales
$34.47 million
Book Value
$6.14 per share

Miscellaneous

Free Float
26,398,000
Market Cap
$1.76 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Reza Zadno Ph.D. (Age 67)
    Pres, CEO & Director
    Comp: $759.5k
  • Mr. Kevin Waters (Age 45)
    Exec. VP & CFO
    Comp: $543.38k
  • Mr. Hisham Shiblaq (Age 46)
    Exec. VP & Chief Commercial Officer
    Comp: $507.5k
  • Mr. Mohan F. Sancheti (Age 58)
    Sr. VP of Operations
  • Ms. Alaleh Nouri (Age 43)
    EVP, Chief Legal Officer & Corp. Sec.
  • Ms. Minni Vittal
    Sr. VP & Chief People Officer
  • Mr. Bijesh Chandran
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Mr. Matthew P. Salkeld
    Sr. VP of Health Care, Economics & Reimbursement
  • Mr. Barry Templin
    Sr. VP of Clinical & Medical Affairs
  • Dr. Thomas J. Yorkey Ph.D. (Age 60)
    Sr. VP of R&D













PRCT Stock - Frequently Asked Questions

Should I buy or sell PROCEPT BioRobotics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRCT shares.
View PRCT analyst ratings
or view top-rated stocks.

What is PROCEPT BioRobotics' stock price forecast for 2022?

8 Wall Street analysts have issued 1-year price targets for PROCEPT BioRobotics' shares. Their PRCT share price forecasts range from $30.00 to $53.00. On average, they expect the company's stock price to reach $43.50 in the next year. This suggests a possible upside of 10.0% from the stock's current price.
View analysts price targets for PRCT
or view top-rated stocks among Wall Street analysts.

How have PRCT shares performed in 2022?

PROCEPT BioRobotics' stock was trading at $25.01 at the beginning of the year. Since then, PRCT stock has increased by 58.1% and is now trading at $39.54.
View the best growth stocks for 2022 here
.

When is PROCEPT BioRobotics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PRCT earnings forecast
.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) released its quarterly earnings results on Thursday, August, 4th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.06. PROCEPT BioRobotics had a negative net margin of 138.49% and a negative trailing twelve-month return on equity of 26.41%.

What guidance has PROCEPT BioRobotics issued on next quarter's earnings?

PROCEPT BioRobotics updated its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $66.00 million-$68.00 million, compared to the consensus revenue estimate of $61.51 million.

When did PROCEPT BioRobotics IPO?

(PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share.

What is PROCEPT BioRobotics' stock symbol?

PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol "PRCT."

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (13.42%), Price T Rowe Associates Inc. MD (8.76%), Driehaus Capital Management LLC (1.71%), State Street Corp (1.02%), Massachusetts Financial Services Co. MA (0.76%) and Northern Trust Corp (0.43%). Insiders that own company stock include Alaleh Nouri, Global Investors Lp Viking, Morgan Colby Wood and Thomas M Krummel.
View institutional ownership trends
.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PROCEPT BioRobotics' stock price today?

One share of PRCT stock can currently be purchased for approximately $39.54.

How much money does PROCEPT BioRobotics make?

PROCEPT BioRobotics (NASDAQ:PRCT) has a market capitalization of $1.76 billion and generates $34.47 million in revenue each year. The company earns $-59,850,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis.

How many employees does PROCEPT BioRobotics have?

The company employs 234 workers across the globe.

How can I contact PROCEPT BioRobotics?

PROCEPT BioRobotics' mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The official website for the company is www.procept-biorobotics.com. The company can be reached via phone at 650-232-7200 or via email at ir@procept-biorobotics.com.

This page (NASDAQ:PRCT) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.